Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patien...
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
About this item
Full title
Author / Creator
Kawamoto, Yasuyuki , Yuki, Satoshi , Sawada, Kentaro , Nakamura, Michio , Muto, Osamu , Sogabe, Susumu , Shindo, Yoshiaki , Ishiguro, Atsushi , Sato, Atsushi , Tsuji, Yasushi , Dazai, Masayoshi , Okuda, Hiroyuki , Meguro, Takashi , Harada, Kazuaki , Sekiguchi, Mari , Okada, Kazufumi , Ito, Yoichi M , Sakata, Yuh , Sakamoto, Naoya and Komatsu, Yoshito
Publisher
US: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
US: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Abstract
Background
Ramucirumab is a human IgG1 monoclonal vascular endothelial growth factor receptor-2 antibody that inhibits tumor cell growth and affects the tumor cell microenvironment. We assessed the efficacy and safety of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with previously treated advan...
Alternative Titles
Full title
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
Authors, Artists and Contributors
Author / Creator
Yuki, Satoshi
Sawada, Kentaro
Nakamura, Michio
Muto, Osamu
Sogabe, Susumu
Shindo, Yoshiaki
Ishiguro, Atsushi
Sato, Atsushi
Tsuji, Yasushi
Dazai, Masayoshi
Okuda, Hiroyuki
Meguro, Takashi
Harada, Kazuaki
Sekiguchi, Mari
Okada, Kazufumi
Ito, Yoichi M
Sakata, Yuh
Sakamoto, Naoya
Komatsu, Yoshito
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9355819
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9355819
Other Identifiers
ISSN
1083-7159
E-ISSN
1549-490X
DOI
10.1093/oncolo/oyac086
